koaguleringfaktorkoncentrat

Koaguleringfaktorkoncentrat, also known as clotting factor concentrate, are pharmaceutical preparations derived from human blood plasma or produced through recombinant DNA technology. These concentrates contain specific clotting factors that are deficient or defective in individuals with certain bleeding disorders, most notably hemophilia A and hemophilia B.

Hemophilia A is characterized by a deficiency in clotting factor VIII, while hemophilia B results from a deficiency in clotting factor IX. Without sufficient levels of these factors, blood does not clot properly, leading to prolonged bleeding episodes, which can occur internally or externally. Koaguleringfaktorkoncentrat are administered intravenously to raise the blood levels of the deficient clotting factor, thereby enabling the blood to clot and stop bleeding.

These concentrates can be used to treat active bleeding episodes, to prevent bleeding during surgery or invasive procedures, and in some cases, for routine prophylaxis to prevent spontaneous bleeding. Different types of concentrates exist, including those derived from plasma and those produced using recombinant technology. Recombinant concentrates offer a reduced risk of transmission of infectious diseases compared to plasma-derived products. The choice of concentrate and the dosage depend on the specific type and severity of the bleeding disorder, the patient's weight, and the clinical situation. Proper administration and monitoring are crucial for effective treatment.